David Kirakossian, MD
Rheumatology · Portland
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Northwest Rheumatology Associates, PC · 6 clinicians in this group
Hospitals listed: Columbia Memorial Hospital · Hillsboro Medical Center · OHSU Hospital and Clinics · Providence Seaside Hospital · Providence St Vincent Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Kirakossian’s office at (503) 297-3384 to ask if they take your plan before you enroll.
California Medical Board record
Licence A150426 · Delinquent
Licence status: Delinquent · since 2017 · expires 2023-05-31 · University of Pittsburgh School of Medicine.
License renewal fee has not been paid. No practice is permitted.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Columbia Memorial HospitalAstoria, ORCritical Access Hospital · Proprietary · Has an emergency departmentPatients rate it 4 of 5 · 81% would definitely recommend itNo overall ratingNo measure marked better or worse than the national rate
- Hillsboro Medical CenterHillsboro, ORAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Oregon Health and Science University, which runs 2 hospitalsPatients rate it 3 of 5 · 62% would definitely recommend itOverall rating: 3 of 5 starsNo measure marked better or worse than the national rate
- OHSU Hospital and ClinicsPortland, ORAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Oregon Health and Science University, which runs 2 hospitalsHome of Knight Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 3 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.31 (1.1 to 1.51), Jul 2022 – Jun 2024Worse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 6.83 (5.37 to 8.29) · 3,784 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.733, Oct 2024 – Sep 2025
- Providence Seaside HospitalSeaside, ORCritical Access Hospital · Voluntary non-profit - Church · Has an emergency department · Birthing-friendlyPart of Providence, which runs 54 hospitals in 7 statesPatients rate it 4 of 5 · 79% would definitely recommend itOverall rating: 3 of 5 starsNo measure marked better or worse than the national rate
- Providence St Vincent Medical CenterPortland, ORAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Providence, which runs 54 hospitals in 7 statesPatients rate it 4 of 5 · 79% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 0.76 (0.53 to 0.99), Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.151, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.346, Oct 2024 – Sep 2025
See every measure and the patient survey for Columbia Memorial Hospital
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.3 (4.3 to 9.3) · 166 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.5 (6.8 to 13.1) · 166 cases | No different | Jan 2024 – Dec 2024 |
What patients said (298 patients answered, 34% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 4 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 4 |
| Recommend hospital | 5 |
| Room was "always" clean | 72% |
| Nurses "always" communicated well | 83% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 69% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 81% |
| Doctors "always" treated them with courtesy and respect | 88% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 82% |
| Nurses "always" treated them with courtesy and respect | 90% |
| "Always" quiet at night | 58% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 60% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Hillsboro Medical Center
Behind the star rating — Deaths: 0 better, 6 the same, 0 worse of 6 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 0 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.28 (0.22 to 2.35) · 271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1 (0.57 to 1.43) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 9.8 · 33 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12 · 39 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.4 · 126 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.3 · 133 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.3 · 128 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.1 · 1,273 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.03 to 0.49) · 1,713 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.38 (0.17 to 0.59) · 1,706 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (0.63 to 5.64) · 266 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.58 (0 to 3.26) · 101 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.22 (0.52 to 3.91) · 255 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.06 (0 to 17.5) · 102 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.85 (0.67 to 9.03) · 94 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.26) · 79 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.76 (0 to 1.76) · 1,439 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 26 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.564 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 2.086 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.755 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.541 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.8 · 62 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.4 · 300 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 30.7 · 137 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 50.8 · 128 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.4 · 290 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.9 (3 to 7.5) · 40 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.6 (7.3 to 15.1) · 40 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.5 · 105 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.4 (8.6 to 15) · 967 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.4) · 236 cases | No different | Jan 2024 – Dec 2024 |
What patients said (718 patients answered, 20% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 2 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 64% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 62% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 62% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for OHSU Hospital and Clinics
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 1 better, 8 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.31 (1.1 to 1.51) | Worse | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 6.83 (5.37 to 8.29) · 3,784 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.733 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.38 (0.61 to 2.14) · 2,275 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 150.45 (118.94 to 181.96) · 340 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3 · 44 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.3 · 98 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.6 · 197 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.7 · 145 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.7 · 273 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 3,434 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.25 (0.07 to 0.43) · 7,501 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.06 to 0.42) · 7,980 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.42 (1.27 to 3.57) · 2,337 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.27 (1.24 to 3.31) · 3,615 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.99 (7.55 to 14.42) · 2,153 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.35 (5.23 to 9.48) · 2,355 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.98 (0.69 to 3.27) · 1,001 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.66 (0.18 to 1.14) · 6,661 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.2 · 56 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.838 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.8 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.936 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 1.381 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.174 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 180 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.3 · 320 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 11.9 · 120 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 7.9 · 223 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.5 · 142 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.6 · 204 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5 (3.9 to 6.3) · 952 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.5 (8 to 11.4) · 952 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.8 · 47 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.4 · 88 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 49 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.8 (9.1 to 15.4) · 1,483 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 1,425 cases | No different | Jan 2024 – Dec 2024 |
What patients said (812 patients answered, 24% of those asked)
| Cleanliness | 2 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 64% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 51% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 49% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
See every measure and the patient survey for Providence Seaside Hospital
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 0 better, 1 the same, 0 worse of 1 measures. Readmissions: 0 better, 5 the same, 1 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate for COPD patientsComplications and deaths | 7.2 · 29 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 95 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.3 · 33 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 349 cases | None | Jul 2024 – Jun 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.422 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 1.17 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.3 · 85 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 32.4 · 97 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -20.6 · 84 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 71 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.4 to 7.9) · 59 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.5 (6.6 to 13.3) · 59 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 36 cases | None | Jul 2023 – Jun 2025 |
What patients said (177 patients answered, 22% of those asked)
| Cleanliness | 3 |
| Nurse communication | 5 |
| Doctor communication | 4 |
| Communication about medicines | 4 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 69% |
| Nurses "always" communicated well | 83% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 69% |
| Yes, staff "did" give patients this information | 90% |
| Yes, staff "did" give patients information about help after discharge | 91% |
| Doctors "always" explained things so they could understand | 77% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 88% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 81% |
| Nurses "always" explained things so they could understand | 78% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 90% |
| "Always" quiet at night | 56% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 56% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
See every measure and the patient survey for Providence St Vincent Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 4 better, 4 the same, 0 worse of 8 measures. Readmissions: 0 better, 7 the same, 2 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.76 (0.53 to 0.99) | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.151 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.346 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.94 (0.03 to 1.86) · 1,383 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 210.44 (170.37 to 250.51) · 136 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.8 · 142 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 5.7 · 109 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.3 · 277 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.7 · 600 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.6 · 344 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.2 · 622 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 6,349 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.28 (0.1 to 0.45) · 8,844 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.04 to 0.41) · 9,136 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.24 (0.57 to 3.92) · 2,901 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.32 (0.09 to 2.54) · 1,299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.59 to 3.03) · 2,665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (4.78 to 12.29) · 1,373 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4 (1.14 to 6.86) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.54 (0.11 to 2.97) · 453 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.32 (0 to 0.84) · 7,487 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.2 · 136 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.732 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.678 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.806 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.625 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.7 · 1,318 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5 · 369 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6 · 724 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 352 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.7 · 647 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 164 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.7 · 171 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21 · 241 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (10.5 to 18.3) · 583 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.3 (1 to 1.6) · 579 cases | No different | Jan 2024 – Dec 2024 |
What patients said (421 patients answered, 24% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 73% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 56% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$1,079,612
Medicare paid this office $1,079,612 for 408 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 27 | $190,811 | None |
| Injection, rituximab, 10 mg | 17 | $189,494 | None |
| Injection, golimumab, 1 mg, for intravenous use | 50 | $169,362 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 41 | $91,704 | None |
| Injection, romosozumab-aqqg, 1 mg | 15 | $74,213 | None |
See all 19 services
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 27 | $190,811 | None |
| Injection, rituximab, 10 mg | 17 | $189,494 | None |
| Injection, golimumab, 1 mg, for intravenous use | 50 | $169,362 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 41 | $91,704 | None |
| Injection, romosozumab-aqqg, 1 mg | 15 | $74,213 | None |
| Injection, denosumab, 1 mg | 46 | $70,937 | None |
| Injection, tocilizumab, 1 mg | 12 | $61,200 | None |
| Return visit (30+ min) | 177 | $31,085 | $93 |
| Administration of chemotherapy into vein, 1 hour or less | 117 | $21,152 | $104 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 105 | $9,272 | $45 |
| New patient visit (45+ min) | 62 | $7,638 | $123 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 206 | $4,554 | $12 |
| Administration of chemotherapy into vein, each additional hour | 67 | $3,851 | $22 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 21 | $1,528 | $61 |
| Short return visit (20+ min) | 16 | $1,194 | $75 |
| Injection of drug or substance under skin or into muscle | 54 | $940 | $11 |
| Injection, zoledronic acid, 1 mg | 38 | $871 | None |
| Injection of additional new drug or substance into vein | 22 | $490 | $12 |
| Injection, methylprednisolone sodium succinate, 5 mg | 19 | $54 | None |
Who their Medicare patients are
408 Original Medicare patients in 2024. Average age 73 · Under 65 8% · 85 and older 6% · Women 78% · Also on Medicaid 7% · Health risk score 1.34. At or below the middle of the specialty; the typical rheumatology clinician is at 1.38.
Conditions among them: High blood pressure 62% · Chronic kidney disease 23% · Depression 23% · Diabetes 18% · Coronary heart disease 15% · Heart failure 13% · Cancer 12% · Atrial fibrillation 12% · COPD 10% · Dementia 4% · Stroke 4%.
The office billed $3,477,351, Medicare allowed $1,369,118 and paid $1,079,612; for 66,419 services of 44 kinds; $996,363 of it was for drugs given in the office and $83,249 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 408 | 66,419 | 73 | 1.34 | $3,477,351 | $1,079,612 |
| 2023 | 388 | 70,433 | 73 | 1.32 | $3,136,011 | $1,079,265 |
| 2022 | 177 | 23,394 | 73 | 1.39 | $895,542 | $320,572 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Injection, golimumab, 1 mg, for intravenous use | 57 | $257,454 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 20 | $148,327 | None |
| Injection, tocilizumab, 1 mg | 16 | $112,246 | None |
| Injection, denosumab, 1 mg | 58 | $73,021 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 30 | $71,963 | None |
| Return visit (30+ min) | 168 | $27,812 | $89 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 123 | $13,844 | $48 |
| Administration of chemotherapy into vein, 1 hour or less | 47 | $10,688 | $103 |
| New patient visit (45+ min) | 63 | $7,828 | $124 |
| Administration of chemotherapy into vein, each additional hour | 47 | $2,949 | $23 |
| Injection, zoledronic acid, 1 mg | 30 | $1,007 | None |
| Injection of drug or substance under skin or into muscle | 68 | $909 | $10 |
| Injection of additional new drug or substance into vein | 18 | $466 | $13 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 15 | $92 | None |
2022: 11 services
| Injection, golimumab, 1 mg, for intravenous use | 23 | $85,231 | None |
| Injection, tocilizumab, 1 mg | 11 | $47,235 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 21 | $44,714 | None |
| Injection, denosumab, 1 mg | 14 | $14,800 | None |
| Return visit (30+ min) | 74 | $8,655 | $103 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 51 | $5,232 | $57 |
| Administration of chemotherapy into vein, 1 hour or less | 26 | $4,838 | $115 |
| New patient visit (45+ min) | 16 | $2,025 | $127 |
| Short return visit (20+ min) | 27 | $1,853 | $69 |
| Administration of chemotherapy into vein, each additional hour | 26 | $1,142 | $24 |
| Injection of drug or substance under skin or into muscle | 15 | $177 | $12 |
Medicaid work
$2,986 in 2024
Medicaid paid $2,986 for 88 billed services this clinician did in 2024, up to 20 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 47 | $2,716 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 41 | $270 |
| 2024 | 88 | 2 | 20 | $2,986 |
Drugs they prescribed that Part D paid
$1,585,863
Pharmacies billed $1,585,863 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (34 of 2,259) in 2024. At or below the middle of the specialty; the typical rheumatology clinician is at 3%.
1,870 generic and 374 brand-name prescriptions · $1,585,863 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Enbrel Sureclick | 83 | $638,725 | $7,695 |
| Xeljanz Xr | 38 | $258,287 | $6,797 |
| Rinvoq | 37 | $244,061 | $6,596 |
| Humira | 12 | $78,652 | $6,554 |
| Hydroxychloroquine Sulfate | 335 | $16,039 | $48 |
See all 25 drugs
| Enbrel Sureclick | 83 | $638,725 | $7,695 |
| Xeljanz Xr | 38 | $258,287 | $6,797 |
| Rinvoq | 37 | $244,061 | $6,596 |
| Humira | 12 | $78,652 | $6,554 |
| Hydroxychloroquine Sulfate | 335 | $16,039 | $48 |
| Methotrexate | 391 | $13,298 | $34 |
| Prednisone | 441 | $5,134 | $12 |
| Leflunomide | 94 | $4,810 | $51 |
| Mycophenolate Mofetil | 27 | $4,103 | $152 |
| Sulfasalazine Dr | 73 | $4,073 | $56 |
| Sulfasalazine | 56 | $2,879 | $51 |
| Azathioprine | 40 | $2,733 | $68 |
| Colchicine | 32 | $1,737 | $54 |
| Celecoxib | 56 | $1,437 | $26 |
| Allopurinol | 58 | $1,049 | $18 |
| Alendronate | 98 | $837 | $9 |
| Gabapentin | 19 | $808 | $43 |
| Folic Acid | 81 | $705 | $9 |
| Tramadol | 27 | $394 | $15 |
| Diclofenac | 12 | $394 | $33 |
| Methotrexate | 18 | $297 | $16 |
| Cyclobenzaprine | 27 | $272 | $10 |
| Pregabalin | 13 | $255 | $20 |
| Duloxetine | 11 | $178 | $16 |
| Meloxicam | 22 | $114 | $5 |
Year by year
| 2024 | 2,259 | 398 | 2% (34) | 17% | $1,585,863 |
| 2023 | 1,737 | 329 | 2% (29) | 14% | $1,146,148 |
| 2022 | 705 | 249 | 2% (11) | None | $623,461 |
| 2021 | 354 | 59 | 0% (0) | None | $347,917 |
| 2020 | 69 | 22 | 0% (0) | None | $65,314 |
| 2019 | 25 | 15 | 0% (0) | None | $1,367 |
| 2018 | 111 | 51 | 0% (0) | 22% | $6,805 |
| 2017 | 71 | 28 | 0% (0) | 18% | $2,448 |
| 2016 | 41 | 13 | 0% (0) | None | $4,754 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 26 drugs
| Enbrel Sureclick | 60 | $442,877 | $7,381 |
| Xeljanz Xr | 36 | $254,389 | $7,066 |
| Rinvoq | 18 | $110,934 | $6,163 |
| Humira(Cf) | 11 | $83,039 | $7,549 |
| Humira | 11 | $74,930 | $6,812 |
| Hydroxychloroquine Sulfate | 225 | $18,877 | $84 |
| Methotrexate | 276 | $14,738 | $53 |
| Leflunomide | 115 | $9,039 | $79 |
| Prednisone | 345 | $4,585 | $13 |
| Sulfasalazine Dr | 48 | $4,340 | $90 |
| Mycophenolate Mofetil | 12 | $2,601 | $217 |
| Sulfasalazine | 45 | $2,131 | $47 |
| Azathioprine | 24 | $1,853 | $77 |
| Colchicine | 19 | $1,185 | $62 |
| Gabapentin | 30 | $1,098 | $37 |
| Diclofenac | 26 | $1,002 | $39 |
| Celecoxib | 28 | $919 | $33 |
| Allopurinol | 39 | $864 | $22 |
| Alendronate | 80 | $818 | $10 |
| Tramadol | 23 | $436 | $19 |
| Duloxetine | 27 | $350 | $13 |
| Folic Acid | 36 | $258 | $7 |
| Methotrexate | 14 | $253 | $18 |
| Meloxicam | 27 | $208 | $8 |
| Cyclobenzaprine | 29 | $131 | $5 |
| Magnesium Sulfate | 11 | $15 | $1 |
2022: 13 drugs
| Enbrel Sureclick | 20 | $173,110 | $8,655 |
| Simponi | 11 | $107,284 | $9,753 |
| Methotrexate | 130 | $6,015 | $46 |
| Leflunomide | 41 | $4,957 | $121 |
| Hydroxychloroquine Sulfate | 60 | $4,546 | $76 |
| Azathioprine | 31 | $2,339 | $75 |
| Prednisone | 124 | $1,873 | $15 |
| Sulfasalazine Dr | 11 | $1,027 | $93 |
| Sulfasalazine | 17 | $1,020 | $60 |
| Gabapentin | 19 | $462 | $24 |
| Alendronate | 24 | $294 | $12 |
| Meloxicam | 23 | $261 | $11 |
| Methotrexate | 11 | $231 | $21 |
2021: 10 drugs
| Enbrel Sureclick | 17 | $106,382 | $6,258 |
| Humira(Cf) | 11 | $62,739 | $5,704 |
| Methotrexate | 68 | $2,100 | $31 |
| Colchicine | 13 | $2,100 | $162 |
| Leflunomide | 18 | $2,052 | $114 |
| Hydroxychloroquine Sulfate | 21 | $1,791 | $85 |
| Azathioprine | 22 | $1,769 | $80 |
| Prednisone | 63 | $733 | $12 |
| Alendronate | 13 | $136 | $10 |
| Sulfamethoxazole-Trimethoprim | 20 | $46 | $2 |
2020: 1 drug
| Methotrexate | 14 | $418 | $30 |
Money from drug and device companies
$84 in 2025
| 2025 | 1 | 2 | None | $84 |
| 2023 | 1 | 1 | None | $60 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Amgen | Krystexxa | $84 | 2 payments
|
See all 2 published payments
| Amgen | Meals · 2025-07-15 | Evenity | $14 |
| Amgen | Meals · 2025-03-20 | Krystexxa | $70 |
See earlier years (2023)
2023: $60
| Janssen Biotech | Tremfya | $60 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 93.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1215399308
- Licence
- CA A150426, OR MD209272California A150426: Delinquent · expires 2023-05-31
- Trained
- University of Pittsburgh School of Medicine, 2016
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RR0500X (207RR0500X); Internal medicine (207R00000X); Student in a training program (390200000X)
- Mailing address
- 9555 Sw Barnes Rd Ste 150, Portland, OR, 97225
- NPI first listed
- 2016-03-28
- NPI last updated
- 2022-07-19
- NPI record certified
- 2022-07-19
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 3181 Sw Sam Jackson Park Rd, Portland, OR, 97239 · 710 Lawrence Expy, Santa Clara, CA, 95051